Physician profile
Arjun D Aneja
NPI 1972690444
$5,531.56
in general payments reported to CMS, 2019-2025
22 companies · $882 in 2025
The $882 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $599 · 2020: $291 · 2021: $775 · 2022: $937 · 2023: $888 · 2024: $1,160 · 2025: $882.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,912 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,911.76 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,249.47 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,351.21 | 2019-2025 | Breztri, Airsupra, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $621.32 | 2019-2024 | Ofev |
| Genzyme Corporation | $266.86 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $164.04 | 2021-2025 | Glassia |
| Regeneron Healthcare Solutions, INC. | $152.73 | 2024-2025 | Dupixent |
| Grifols USA, LLC | $106.67 | 2019-2025 | Xembify |
| Mylan Specialty L.P. | $90.95 | 2024 | Yupelri |
| Baxter Healthcare | $81.11 | 2022 | |
| Viatris Specialty LLC | $75.08 | 2025 | Yupelri |
| Pulmonx Corporation | $62.60 | 2023-2024 | Chartis Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Atricure, INC. | $48.74 | 2024 | |
| Vifor Pharma, INC. | $45.42 | 2024-2025 | Zemaira |
| Merck Sharp & Dohme LLC | $42.33 | 2023 | |
| Insmed, INC. | $39.88 | 2025 | Brinsupri, Arikayce |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $28.60 | 2023 | Acthar |
| Inogen, INC. | $22.10 | 2023 | Inogen |
| Electromed, INC. | $20.89 | 2023 | Smartvest |
| Vapotherm INC | $17.98 | 2022 | |
| Lilly USA, LLC | $17.01 | 2025 | Zepbound |
| Amgen INC. | $13.69 | 2025 | Tezspire |
| Gilead Sciences, INC. | $12.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arjun Aneja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.